NO984543L - Bioaktiverte diagnostiske imaging kontrastmidler - Google Patents

Bioaktiverte diagnostiske imaging kontrastmidler

Info

Publication number
NO984543L
NO984543L NO984543A NO984543A NO984543L NO 984543 L NO984543 L NO 984543L NO 984543 A NO984543 A NO 984543A NO 984543 A NO984543 A NO 984543A NO 984543 L NO984543 L NO 984543L
Authority
NO
Norway
Prior art keywords
agents
bioactivated
contrast agents
diagnostic imaging
imaging contrast
Prior art date
Application number
NO984543A
Other languages
English (en)
Other versions
NO984543D0 (no
NO319674B1 (no
Inventor
Randall B Lauffer
Thomas J Mcmurry
Stephen O Dunham
Daniel M Scott
David J Parmelee
Stuphane Dumas
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of NO984543D0 publication Critical patent/NO984543D0/no
Publication of NO984543L publication Critical patent/NO984543L/no
Publication of NO319674B1 publication Critical patent/NO319674B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
NO19984543A 1996-04-01 1998-09-29 Bioaktiverte diagnostiske imaging kontrastmidler NO319674B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1444896P 1996-04-01 1996-04-01
PCT/US1997/004804 WO1997036619A2 (en) 1996-04-01 1997-03-25 Bioactivated diagnostic imaging contrast agents

Publications (3)

Publication Number Publication Date
NO984543D0 NO984543D0 (no) 1998-09-29
NO984543L true NO984543L (no) 1998-11-26
NO319674B1 NO319674B1 (no) 2005-09-05

Family

ID=21765541

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19984543A NO319674B1 (no) 1996-04-01 1998-09-29 Bioaktiverte diagnostiske imaging kontrastmidler

Country Status (19)

Country Link
US (3) US6709646B2 (no)
EP (1) EP0907379B1 (no)
JP (2) JP2000507577A (no)
KR (1) KR20060025233A (no)
CN (1) CN1108824C (no)
AT (1) ATE268187T1 (no)
AU (1) AU726914B2 (no)
BR (1) BR9708470A (no)
CA (1) CA2247620A1 (no)
DE (1) DE69729380T2 (no)
DK (1) DK0907379T3 (no)
ES (1) ES2217408T3 (no)
HK (1) HK1016877A1 (no)
IL (1) IL125895A (no)
IS (1) IS2059B (no)
NO (1) NO319674B1 (no)
NZ (1) NZ331629A (no)
PT (1) PT907379E (no)
WO (1) WO1997036619A2 (no)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6675035B1 (en) * 1997-06-20 2004-01-06 Imaging Diagnostic Systems, Inc. Phantom for optical and magnetic resonance imaging quality control
NZ503402A (en) * 1997-10-02 2002-03-01 Epix Medical Inc Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
WO1999021592A1 (en) * 1997-10-27 1999-05-06 California Institute Of Technology Magnetic resonance imaging agents for the delivery of therapeutic agents
CA2309749A1 (en) 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
IT1297034B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
US6167297A (en) 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6230586B1 (en) * 1999-05-21 2001-05-15 Chung-Hsi Chang Electric drive device for a bicycle
MXPA02001017A (es) 1999-07-29 2002-08-12 Epix Medical Inc Agente multimerico de formacion de imagenes con especificidad hacia el blanco mediante su union a multiples regiones.
AU2001231090A1 (en) * 2000-01-22 2001-07-31 Epix Medical, Inc. Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
CA2407450A1 (en) * 2000-05-04 2001-11-08 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
EP1283728A2 (en) * 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
US6748259B1 (en) 2000-06-15 2004-06-08 Spectros Corporation Optical imaging of induced signals in vivo under ambient light conditions
WO2002006287A2 (en) 2000-07-17 2002-01-24 California Institute Of Technology Macrocyclic mri contrast agents
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
DE60322076D1 (de) * 2002-07-22 2008-08-21 Bracco Imaging Spa Zellmarkierungsverfahren mit paramagnetischen komplexen für mrt-anwendungen
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
WO2004078778A2 (en) 2003-03-03 2004-09-16 Dyax Corp. PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
FR2868320B1 (fr) * 2004-03-31 2007-11-02 Centre Nat Rech Scient Cnrse Agent de contraste pour l'imagerie par resonance magnetique
EP1863546B1 (en) * 2005-03-11 2015-10-07 Wake Forest University Health Sciences Production of tissue engineered heart valves
EP1863547B1 (en) * 2005-03-11 2016-05-11 Wake Forest University Health Sciences Tissue engineered blood vessels
US20060204445A1 (en) * 2005-03-11 2006-09-14 Anthony Atala Cell scaffold matrices with image contrast agents
US7531503B2 (en) * 2005-03-11 2009-05-12 Wake Forest University Health Sciences Cell scaffold matrices with incorporated therapeutic agents
US8728463B2 (en) * 2005-03-11 2014-05-20 Wake Forest University Health Science Production of tissue engineered digits and limbs
US20060204539A1 (en) * 2005-03-11 2006-09-14 Anthony Atala Electrospun cell matrices
EP1743658A1 (en) 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
CN101252954A (zh) * 2005-06-30 2008-08-27 布里斯托尔-迈尔斯斯奎布药品公司 作为显像剂的酰肼偶联物
JP5377965B2 (ja) * 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
WO2007084264A2 (en) * 2005-12-29 2007-07-26 Epix Pharmaceuticals, Inc. Methods for myocardial imaging
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JPWO2009054327A1 (ja) * 2007-10-22 2011-03-03 財団法人大阪産業振興機構 Ｍｒｉ用プローブ
WO2010107832A1 (en) 2009-03-17 2010-09-23 Bracco Imaging Spa Lhrh-ii peptide analogs
AU2010226479A1 (en) 2009-03-19 2011-09-22 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) -en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
JP2011026294A (ja) 2009-06-26 2011-02-10 Canon Inc 化合物
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN102188722A (zh) * 2010-03-18 2011-09-21 中国科学院福建物质结构研究所 一种含二价铁的磁共振成像造影剂
US8192429B2 (en) 2010-06-29 2012-06-05 Theravant, Inc. Abnormality eradication through resonance
WO2013131994A2 (en) * 2012-03-08 2013-09-12 Thommen Medical Ag Coating for the diagnosis of inflammatory tissues in dental applications
WO2013131993A2 (en) * 2012-03-08 2013-09-12 Thommen Medical Ag Device for the diagnosis of inflammatory tissues in dental applications
WO2014078484A1 (en) 2012-11-15 2014-05-22 Endocyte, Inc. Conjugates for treating diseases caused by psma expressing cells
US10092679B2 (en) 2013-10-18 2018-10-09 Wake Forest University Health Sciences Laminous vascular constructs combining cell sheet engineering and electrospinning technologies
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
WO2015171543A1 (en) 2014-05-05 2015-11-12 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015196208A2 (en) 2014-06-20 2015-12-23 The General Hospital Corporation Collagen targeted imaging probes
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016149404A1 (en) 2015-03-16 2016-09-22 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
CN108290927B (zh) 2015-07-15 2022-06-24 加州理工学院 Il-17f-特异性捕获剂、组合物以及使用和制造的方法
US20170319722A1 (en) 2016-04-04 2017-11-09 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
CA3057976A1 (en) * 2017-04-27 2018-11-01 The Regents Of The University Of California Modified mri contrast agents and uses thereof
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2019075213A1 (en) * 2017-10-11 2019-04-18 Northwestern University HEPARIN CONJUGATED TO PEPTIDES BINDING TO COLLAGEN FOR TARGETING BIOLOGICAL AND SYNTHETIC FABRICS
CN108314695B (zh) * 2018-01-04 2020-06-16 南京邮电大学 一种异种双核金属配合物的制备及应用
US11919972B2 (en) 2018-11-02 2024-03-05 Regeneron Pharmaceuticals, Inc. Peptide libraries with non-canonical amino acids
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
WO2020186091A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US20200371101A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
CN112891566A (zh) * 2019-12-04 2021-06-04 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 一种纳米材料及其制备方法和包含其的造影剂
EP4143227A2 (en) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antibodies
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
ZA877727B (en) * 1986-10-17 1988-06-29 Cytogen Corp Method for preparation of protein-chelator-metal ion compositions suitable for injection
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
US5171563A (en) 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
WO1991003200A1 (en) * 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
EP0664713B1 (en) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutic and diagnostic imaging compositions and methods
EP0731797B1 (en) * 1993-12-03 1999-09-08 BRACCO S.p.A. Paramagnetic chelates for nuclear magnetic resonance diagnosis
DE4341724A1 (de) * 1993-12-03 1995-06-08 Schering Ag Halogenaryl-substituierte Metallkomplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
TW319763B (no) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19507822B4 (de) * 1995-02-21 2006-07-20 Schering Ag Substituierte DTPA-Monoamide der zentralen Carbonsäure und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5707605A (en) * 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents

Also Published As

Publication number Publication date
NO984543D0 (no) 1998-09-29
DE69729380D1 (de) 2004-07-08
CA2247620A1 (en) 1997-10-09
US20020034476A1 (en) 2002-03-21
IL125895A (en) 2001-09-13
US7147837B2 (en) 2006-12-12
WO1997036619A3 (en) 1998-01-29
DK0907379T3 (da) 2004-08-16
KR20060025233A (ko) 2006-03-20
US20040156785A1 (en) 2004-08-12
NZ331629A (en) 2000-04-28
JP2000507577A (ja) 2000-06-20
PT907379E (pt) 2004-09-30
ATE268187T1 (de) 2004-06-15
ES2217408T3 (es) 2004-11-01
CN1215341A (zh) 1999-04-28
BR9708470A (pt) 1999-04-13
IS2059B (is) 2005-10-14
IS4833A (is) 1998-08-26
US6709646B2 (en) 2004-03-23
CN1108824C (zh) 2003-05-21
US20060275216A1 (en) 2006-12-07
NO319674B1 (no) 2005-09-05
AU2544897A (en) 1997-10-22
HK1016877A1 (en) 1999-11-12
EP0907379A2 (en) 1999-04-14
DE69729380T2 (de) 2005-07-14
EP0907379B1 (en) 2004-06-02
JP2004210796A (ja) 2004-07-29
WO1997036619A2 (en) 1997-10-09
IL125895A0 (en) 1999-04-11
AU726914B2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
ATE268187T1 (de) Bioaktivierte diagnostische bilderzeugungskontrastmittel
NO20002380D0 (no) Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering
EP0994352A3 (en) Contrast agent enhanced magnetic resonance imaging of myocardial tissue
YU6502A (sh) Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja
DK0806968T3 (da) Diagnostiske billeddannelseskontrastmidler med foröget blodretention
NO991688L (no) Administrerbare sammensetninger og fremgangsmÕter til magnetisk resonansavbildning
US20100267928A1 (en) Activatable diagnostic and therapeutic compound
NO20002517L (no) Magnetisk resonansavbildningsmidler for deteksjon av fysiologiske midler
WO2001082864A3 (en) 18f-labeled choline analogs
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
NO20002115D0 (no) Magnetisk resonansavbilding for leveringen av terapeutiske midler
WO2003088823A3 (en) Novel macrocyclic activatible magnetic resonance imaging contrast agents
GB0130305D0 (en) Compounds for imaging alzheimers disease
DK0759785T3 (da) Liposomsuspensioner som blodkontrastmidler
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
TR200103562T2 (tr) Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
DE69732370D1 (de) Spinresonanz kontrastmittel für das blut
IT8719808A0 (it) Agenti di contrasto per imaging nmr e relativo metodo diagnostico.